Page 2 - DDI Pad Tear Sheets-14Clickable
P. 2

NOTICE OF POTENTIAL DRUG-DRUG INTERACTIONS


             Darolutamide
              Drug effects                     Drug effects               Darolutamide effects     Darolutamide effects
          Avoid combination:                Monitor/Modify:            Monitor/Modify:         Avoid combination:
            Rosuvastatin 4                    Clozapine 1                Clarithromycin 1        Carbamazepine 1
                                              Nimodipine 1               Itraconazole 1,4        Phenytoin 1
                                                                         Ketoconazole 1
             Enzalutamide

              Drug effects      Drug effects                              Enzalutamide effects     Enzalutamide effects
                            Avoid combination:  Monitor/Modify  Monitor/Modify    Avoid combination:
                              Atorvastatin 5   Alfuzosin   1  cont.:    Gemfibrozil 5
                              Bisoprolol 5  Alprazolam 1  Oxcarbazepine 1
                              Carbamazepine a,1,5  Amiodarone 1  Oxycodone 1  Monitor/Modify:
                                                                         Lefiunomide
                                                                               1
                              Clarithromycin b,1,5  Amlodipine 1  Perampanel 1
                              Clonazepam 5  Apixaban 1  Prednisone 1
                              Clopidogrel 5  Aripiprazole 1  Quetiapine 1
                              Dabigatran 5  Brexpiprazole 1  Repaglinide 1
                              Diazepam 5  Chlordiazepoxide 1  Risperidone 1
                              Digoxin 5   Citalopram 1  Rivaroxaban 1
                              Diltiazem 5   Clozapine   1  Saxagliptin 1
                              Doxycycline 5  Codeine 1  Sertraline 1
                              Dronedarone 1  Cyclosporine 1  Sildenafil 1
                              Felodipine 5  Darifenacin 1  Silodosin 1
                              Fentanyl 1,5  Dexamethasone 1  Solifenacin 1
                              Haloperidol 5  Diclofenac 1  Tadalafil 1
                              Itraconazole 1  Doxazosin 1  Tamsulosin 1
                              Lurasidone 1  Erythromycin 1  Trazodone 1
                              Nifedipine 1,5  Escitalopram 1  Triazolam 1
                              Nimodipine 1  Ethosuximide 1  Voriconazole 1
                              Omeprazole 5  Fesoterodine    Zolpidem 1
                                                   1
                              Phenobarbital 5  Flurazepam 1  Zopiclone 1
                              Phenytoin 1,5  Fluvastatin   1
                              Primidone 5  Gliclazide 1
                              Propranolol 5  Glimepiride 1
                              Simvastatin 5  Glyburide 1
                              Ticagrelor 1  Ketoconazole 1
                              Tramadol 5  Lansoprazole 1
                              Valproic acid 5  Linagliptin 1
                              Verapamil 5  Losartan 1
                              Vorapaxar 1   Lovastatin   1
                              Warfarin 5  Methadone 1
        a.  Enzalutamide may decrease carbamazepine concentration. Carbamazepine may decrease enzalutamide concentration.
        b.   Enzalutamide may increase serum concentrations of clarithromycin active metabolite(s) and decrease clarithromycin concentration. Clarithromycin may increase enzalutamide concentration.

          Recommended actions/actions taken regarding the drug interaction(s), other drug interactions   Practitioner Name
          not listed, or additional notes:










        Disclaimer: The drug-drug interaction tables presented in this resource include a selection of medications commonly encountered in patients undergoing treatment for prostate cancer and are not
        comprehensive in nature. This resource is intended only to supplement the knowledge of healthcare professionals regarding drug therapy.
                              ®
        References: [1] UpToDate, Inc. Lexicomp  Drug Interactions. Available at: www.uptodate.com. Accessed Sep. 2020. [2] ZYTIGA  Product Monograph. Nov.13, 2020.
                                                                             ®
        [3] ERLEADA  Product Monograph. Nov.13, 2020. [4] NUBEQA  Product Monograph. Feb.19, 2020. [5] XTANDI  Product Monograph. Jun.1, 2020.
                                                                    ®
               ®
                                          ®
                                                       Canadian Urological Association
                                                       185 Dorval Avenue, Suite 401
                                                       Dorval, QC  H9S 5J9
                                                       www.cua.org
        This resource has been made possible through funding from Bayer Inc. in the form of an educational grant.
                                                                                                      NBQ015E   PP-NUB-CA-0107-1
        © Copyright 2020, The Canadian Urological Association                                                 January 2021
   1   2